hematopoiet
stem
cell
transplant
idiopath
pneumonia
syndrom
ip
diffus
alveolar
hemorrhag
dah
periengraft
respiratori
distress
syndrom
perd
acut
lung
injuri
remain
major
caus
earli
posthematopoiet
stem
cell
transplant
hsct
nonrelaps
mortal
pulmonari
function
test
result
transplant
may
help
identifi
group
patient
high
risk
posthsct
respiratori
failur
death
earli
enthusiasm
treatment
idiopath
pneumonia
syndrom
etanercept
dampen
result
recent
studi
adult
hsct
recipi
hematopoiet
blood
marrow
stem
cell
transplant
hsct
import
potenti
cur
treatment
option
patient
benign
malign
hematolog
diseas
past
decad
number
hsct
procedur
perform
unit
state
steadili
increas
allogen
procedur
almost
autolog
procedur
report
past
condit
regimenrel
toxic
greatli
limit
applic
allogen
transplant
younger
patient
without
major
comorbid
howev
develop
reducedintens
condit
ric
nonmyeloabl
regimen
reli
primarili
immunolog
mechan
graft
vs
leukemia
rather
myeloabl
erad
malign
greatli
reduc
earli
toxic
allow
transplant
older
sicker
patient
pulmonari
complic
infecti
noninfecti
occur
hsct
recipi
although
rate
sever
may
differ
base
intens
type
condit
regimen
time
immun
system
reconstitut
procedur
indic
type
transplant
autolog
vs
allogen
presenc
preexist
lung
diseas
era
transplant
recent
studi
report
lower
rate
respiratori
failur
posthsct
complic
tradit
categor
period
defin
distinct
phase
procedur
certain
complic
like
occur
certain
period
phase
includ
follow
despit
advanc
diagnosi
treatment
potent
antimicrobi
agent
prophylaxi
pneumonia
remain
major
caus
death
hsct
infecti
complic
review
detail
articl
issu
focu
articl
earli
phase
noninfecti
pulmonari
complic
hsct
noninfecti
pulmonari
complic
import
caus
earli
death
morbid
hsct
complic
includ
pulmonari
edema
transfusionrel
acut
lung
injuri
trali
sever
sever
acut
lung
injuri
syndrom
togeth
fall
umbrella
term
idiopath
pneumonia
syndrom
ip
druginduc
pneumon
cryptogen
organ
pneumonia
acut
fibrin
organ
pneumonia
condit
may
seen
earli
later
time
period
hsct
briefli
discuss
section
pulmonari
edema
may
seen
first
week
either
autolog
allogen
transplant
larg
volum
fluid
frequent
administ
concurr
condit
regimen
chemotherapi
reduc
toxic
transfus
blood
product
infus
intraven
medic
parenter
nutrit
common
reason
volum
administr
earli
posttranspl
period
hypoalbuminemia
subsequ
develop
chemotherapyinduc
cardiac
dysfunct
andor
renal
failur
increas
propens
develop
hydrostat
pulmonari
edema
rapid
infus
multipl
unit
blood
product
increas
risk
transfusionassoci
circulatori
overload
especi
older
patient
cardiac
andor
renal
dysfunct
lung
injuri
chemotherapi
radiat
blood
transfus
sepsi
may
increas
capillari
permeabl
also
contribut
pulmonari
edema
risk
import
clinic
find
includ
weight
gain
rapid
onset
dyspnea
bibasilar
rale
auscult
hypoxemia
radiograph
find
consist
pulmonari
edema
highresolut
computer
tomographi
ct
chest
scan
characterist
find
includ
interlobular
septal
thicken
bilater
ground
glass
opac
pleural
effus
also
may
seen
close
attent
volum
statu
judici
use
diuret
may
reduc
risk
pulmonari
edema
develop
transfusionrel
lung
injuri
trali
may
occur
hsct
develop
concurr
type
lung
injuri
typic
manifest
within
hour
blood
product
transfus
plasmarich
product
platelet
cryoprecipit
fresh
frozen
plasma
confer
greatest
risk
notabl
case
report
trali
develop
immedi
infus
bone
marrow
graft
patient
develop
acut
onset
dyspnea
often
fever
hypotens
acut
leukopenia
thrombocytopenia
may
seen
distinguish
featur
patient
preengraft
phase
chest
radiograph
cxr
find
similar
patient
type
pulmonari
edema
cardiac
imag
typic
show
normal
left
ventricular
function
mechan
injuri
fulli
elucid
involv
process
initi
traffick
prime
neutrophil
damag
lung
microvasculatur
subsequ
neutrophil
activ
antibodi
transfus
blood
product
direct
human
leukocyt
antigen
hla
human
neutrophil
antigen
neutrophil
also
may
activ
substanc
transfus
blood
bioactiv
lipid
solubl
ligand
activ
neutrophil
releas
proinflammatori
cytokin
reactiv
oxygen
speci
proteas
damag
lung
report
trali
neutropen
patient
support
hypothesi
passiv
transfus
hla
antibodi
also
may
directli
target
antigen
pulmonari
vascular
endothelium
hsct
recipi
may
especi
high
risk
trali
transfus
frequent
requir
mani
patient
underli
system
inflamm
trigger
condit
regimen
toxic
sepsi
graft
versu
host
diseas
gvhd
treatment
support
specif
intervent
reliabl
hasten
recoveri
trali
result
respiratori
failur
requir
mechan
ventil
patient
nontranspl
set
mortal
rate
rang
report
use
restrict
transfus
polici
appear
reduc
risk
notabl
trali
rate
declin
unit
state
past
decad
blood
bank
adopt
trali
mitig
polici
transfus
plasma
donor
low
risk
transmit
alloantibodi
male
nullipar
femal
individu
diffus
pneumon
devast
earli
complic
hsct
infecti
etiolog
identifi
half
case
term
idiopath
pneumonia
syndrom
ip
coin
describ
heterogen
group
noninfecti
acut
lung
injuri
disord
notabl
ip
includ
subset
condit
diffus
alveolar
hemorrhag
dah
periengraft
respiratori
distress
syndrom
perd
share
clinic
featur
risk
factor
distinct
clinic
present
treatment
approach
condit
discuss
separ
patient
ip
develop
acut
onset
cough
dyspnea
without
fever
hypoxemia
diffus
infiltr
cxr
often
progress
quickli
respiratori
failur
bronchoscopi
bronchoalveolar
lavag
bal
assess
infecti
process
recommend
quantit
polymeras
chain
reaction
assay
greatli
expand
capabl
diagnos
occult
respiratori
infect
recent
studi
indic
almost
patient
previous
given
diagnosi
ip
fact
found
detect
pathogen
bal
pathogen
predominantli
respiratori
virus
eg
human
herp
human
rhinoviru
cytomegaloviru
aspergillu
speci
although
treatment
option
mani
infect
remain
limit
rule
underli
infect
would
import
consid
treatment
immunomodulatori
therapi
discuss
later
articl
patholog
find
ip
similar
describ
patient
acut
respiratori
distress
syndrom
ard
diffus
alveolar
damag
interstiti
pneumon
commonli
describ
find
ip
may
occur
hsct
recipi
mortal
rate
exceed
studi
american
thorac
societi
at
propos
updat
definit
ip
includ
clinic
physiolog
radiograph
find
consist
diffus
acut
lung
injuri
specif
exclud
respiratori
dysfunct
due
cardiac
renal
iatrogen
volum
overload
box
ip
typic
occur
first
month
hsct
case
develop
preengraft
earli
postengraft
phase
recent
studi
report
variabl
time
onset
rang
median
day
long
day
transplant
risk
factor
develop
ip
includ
older
age
use
highdos
condit
regimen
includ
total
bodi
irradi
tbi
presenc
highgrad
acut
gvhd
allogen
recipi
physiolog
evid
lung
diseas
transplant
autolog
allogen
hsct
recipi
develop
ip
condit
regimenrel
toxic
thought
central
role
inflict
lung
injuri
support
concept
find
allogen
hsct
recipi
receiv
ric
regimen
lower
rate
ip
studi
fred
hutchinson
cancer
research
center
fhcrc
convent
transplant
recipi
compar
recipi
receiv
nonmyeloabl
condit
even
though
nonmyeloabl
cohort
older
rate
ip
significantli
lower
observ
convent
group
vs
older
patient
age
receiv
myeloablativecondit
regimen
includ
highdos
tbi
appear
especi
high
risk
ip
notabl
nonmyeloabl
convent
condit
regimen
group
presenc
sever
gvhd
confer
increas
risk
ip
highlight
import
alloimmun
respons
amplifi
lung
injuri
studi
although
nonmyeloabl
condit
regimen
group
lower
rate
ip
clinic
manifest
less
sever
occur
respiratori
failur
develop
patient
mortal
exceed
although
pathophysiolog
ip
remain
incomplet
understood
preclin
translat
studi
greatli
inform
knowledg
mechan
lung
injuri
serv
foundat
clinic
trial
investig
therapeut
approach
studi
review
recent
offici
at
research
statement
ip
murin
model
allogen
hsct
demonstr
extens
inflammationinjuri
alveolar
interstiti
bronchial
vascular
tissu
particular
anim
data
suggest
pulmonari
endotheli
cell
damag
caus
directli
condit
regimen
toxic
indirectli
activ
robust
inflammatori
respons
princip
event
develop
ip
cytokin
tumor
necrosi
factoralpha
tnfa
appear
key
mediat
inflammatori
respons
murin
studi
shown
increas
level
donorderiv
tnfa
bal
fluid
lung
tissu
associ
ip
sever
transplant
stem
cell
tnfa
knockout
mice
administr
neutral
tnfbind
antibodi
greatli
reduc
lung
injuri
addit
tnfa
high
level
lipopolysaccharid
lp
endotoxin
also
observ
bal
fluid
mice
lp
compon
cell
membran
gramneg
bacteria
capabl
directli
activ
innat
immun
system
macrophag
immun
cell
produc
tnfa
respons
lp
stimul
murin
model
ip
lp
inject
shown
markedli
increas
lung
injuri
hypothes
condit
regimenrel
injuri
acut
gvhd
gastrointestin
tract
facilit
bacteri
transloc
subsequ
releas
lp
system
ultim
pulmonari
circul
result
product
high
level
proinflammatori
cytokin
includ
tnfa
anim
model
indic
block
effect
tnfa
complet
prevent
ip
numer
mechan
lung
injuri
thought
play
import
role
nevertheless
preclin
data
provid
compel
rational
investig
blockad
tnfa
pathway
human
clinic
trial
ip
treatment
ip
high
intermedi
dose
corticosteroid
gener
ineffect
possibl
except
patient
dah
singlecent
nonrandom
studi
suggest
reduct
shortterm
mortal
administr
solubl
tnfreceptor
etanercept
random
doubleblind
placebocontrol
trial
etanercept
mgkg
twice
weekli
total
dose
methylprednisolon
mgkg
per
day
versu
methylprednisolon
alon
treatment
ip
undertaken
clinic
respons
treatment
defin
surviv
studi
day
discontinu
supplement
oxygen
least
hour
day
sampl
size
patient
target
unfortun
patient
accrual
slow
studi
halt
enrol
patient
although
studi
underpow
definit
conclus
could
made
differ
clinic
respons
seen
ten
patient
etanercept
arm
achiev
clinic
respons
wherea
placebo
arm
met
criteria
respons
also
differ
outcom
day
overal
surviv
year
remain
similarli
poor
group
mortal
treatment
arm
placebo
group
studi
prove
challeng
conduct
almost
patient
etanercept
arm
receiv
fewer
dose
explan
earli
discontinu
studi
drug
investig
report
hesit
continu
blind
treatment
especi
patient
demonstr
earli
clinic
improv
investig
also
comment
improv
shortterm
outcom
studi
group
compar
prior
specul
whether
clinic
characterist
ip
chang
past
decad
fact
studi
patient
receiv
ric
possibl
less
toxic
chemoradi
result
lower
level
tnfa
diminish
likelihood
respons
etanercept
treatment
support
hypothesi
result
recent
multicent
albeit
nonrandom
phase
ii
studi
etanercept
treatment
pediatr
patient
ip
demonstr
signific
shortterm
longterm
benefit
surviv
rate
respect
contrast
adult
studi
pediatr
trial
patient
receiv
ric
regimen
futur
tailor
eg
patient
high
level
tnfa
hsct
recipi
receiv
convent
condit
regimen
approach
treat
patient
ip
could
consid
strategi
would
need
evalu
clinic
trial
despit
result
one
random
studi
adult
absenc
treatment
option
etanercept
remain
therapeut
option
patient
sever
ip
support
treatment
sever
ard
extracorpor
life
support
ecl
increasingli
becom
incorpor
clinic
practic
major
eclsrel
complic
includ
sepsi
hemorrhag
reason
immunosuppress
thrombocytopen
hsct
recipi
gener
consid
candid
type
support
advanc
ecl
technolog
howev
reduc
complic
permit
use
lower
level
even
withhold
system
anticoagul
advanc
case
report
patient
ip
success
bridg
recoveri
ecl
even
receiv
treatment
corticosteroid
etanercept
nevertheless
outcom
patient
ip
remain
gener
poor
adult
patient
risk
bridg
nowher
scenario
insignific
result
extrem
difficult
situat
potenti
alert
critic
ill
patient
remain
depend
ecl
thu
essenti
ecl
technolog
use
clear
expect
establish
patient
famili
regard
high
likelihood
treatment
failur
anticip
complic
durat
limit
extracorpor
support
factor
medic
team
use
recommend
withdraw
ecl
earli
consult
palli
care
team
avail
may
help
dah
form
ip
distinct
clinic
present
character
develop
dyspnea
fever
multifoc
infiltr
cxr
rapid
progress
respiratori
failur
hemoptysi
may
occur
alway
seen
typic
find
highresolut
ct
scan
includ
diffus
ground
glass
opac
mid
lower
lung
zone
promin
perihilar
region
without
interlobular
septal
thicken
result
crazypav
appear
distinguish
type
ip
bronchoscopi
find
progress
bloodi
return
bal
fluid
sequenti
aliquot
multipl
lung
segment
diagnost
infecti
etiolog
cardiogen
edema
exclud
presenc
hemosiderinladen
macrophag
cytolog
evalu
bal
fluid
also
support
diagnosi
bal
fluid
analysi
howev
compar
postmortem
studi
appear
suboptim
sensit
specif
diagnosi
dah
studi
also
shown
diffus
alveolar
damag
common
concurr
find
similar
type
ip
dah
seen
autolog
allogen
transplant
recent
studi
report
incid
although
dah
type
ip
overlap
risk
factor
older
age
sever
acut
gvhd
allogen
recipi
intens
condit
regimen
especi
highdos
tbi
cyclophosphamid
treatment
ric
regimen
report
lower
incid
although
thrombocytopenia
almost
univers
present
patient
earli
transplant
appear
common
patient
develop
dah
outcom
although
dah
typic
occur
preperiengraft
time
frame
later
onset
report
case
outcom
report
poor
earlier
public
show
mortal
rate
recent
studi
howev
suggest
surviv
may
improv
studi
consecut
hsct
recipi
underw
bronchoscopi
januari
decemb
univers
texa
md
anderson
cancer
center
patient
identifi
noninfecti
dah
onemonth
surviv
surviv
better
report
mani
previou
studi
type
transplant
time
also
may
impact
outcom
larg
retrospect
seri
mayo
clinic
patient
underw
hsct
octob
june
patient
diagnos
dah
develop
dah
autolog
transplant
earli
onset
within
day
transplant
significantli
better
outcom
approxim
surviv
dah
allogen
transplant
onset
beyond
day
approxim
surviv
treatment
treatment
dah
gener
involv
administr
high
dose
corticosteroid
vari
dose
mg
methylprednisolon
per
day
mgd
day
subsequ
taper
dose
sever
retrospect
analys
report
improv
outcom
contemporari
studi
howev
confirm
benefit
recent
singlecent
report
consecut
hsct
recipi
predominantli
allogen
admit
intens
care
unit
treatment
dah
hsct
overal
mortal
day
notabl
patient
initi
receiv
lower
dose
corticosteroid
mgd
methylprednisolon
reduc
intens
care
unit
hospit
mortal
compar
patient
receiv
higher
dose
howev
random
studi
signific
bia
treatment
decis
relat
underli
sever
ill
exclud
thu
valid
find
uncertain
adjunct
treatment
antifibrinolyt
drug
aminocapro
acid
subset
patient
seem
impact
outcom
unfortun
random
placebocontrol
trial
evalu
therapeut
effect
corticosteroid
vari
dose
treatment
posthsct
dah
conduct
type
trial
would
requir
clinic
equipois
like
exist
practic
nevertheless
result
recent
retrospect
studi
caution
provid
use
high
dose
corticosteroid
limit
avail
treatment
option
dah
led
consider
altern
approach
small
retrospect
seri
patient
dah
explor
use
intraven
treatment
procoagul
agent
recombin
factor
viia
rfviia
conjunct
corticosteroid
report
howev
suggest
clinic
benefit
improv
outcom
treat
patient
appear
increas
risk
thrombot
event
recent
cochran
review
investig
recommend
offlabel
eg
uncontrol
bleed
patient
without
hemophilia
use
rfviia
due
signific
risk
thromboembol
event
recent
investig
explor
direct
intrapulmonari
instil
rfviia
reduc
risk
system
thrombosi
facilit
direct
exposur
drug
site
lung
injuri
although
case
report
small
seri
suggest
possibl
benefit
treatment
approach
endors
without
evid
periengraft
respiratori
distress
syndrom
perd
describ
form
acut
lung
injuri
occur
around
time
engraft
typic
within
day
pulmonari
manifest
diffus
system
capillari
leak
disord
term
engraft
syndrom
es
although
perd
categor
subset
ip
distinct
clinic
present
better
prognosi
es
initi
describ
syngen
autolog
hsct
also
seen
convent
ric
allogen
transplant
fulmin
present
patient
es
may
fever
absenc
infect
erythrodermat
rash
diarrhea
dyspnea
rapid
weight
gain
fluid
retent
hepat
renal
dysfunct
hypotens
rare
hemodynam
collaps
wide
dispar
incid
rate
es
report
literatur
due
part
vari
clinic
definit
patient
popul
exampl
patient
undergo
transplant
poem
polyneuropathi
organomegali
endocrinopathi
monoclon
gammopathi
skin
chang
syndrom
appear
especi
high
risk
es
studi
heterogen
group
autolog
hsct
recipi
perd
report
allogen
set
may
difficult
distinguish
es
acut
gvhd
signific
overlap
clinic
symptom
risk
factor
es
clearli
identifi
although
studi
report
femal
gender
rate
immun
system
reconstitut
peripher
blood
versu
bone
marrow
sourc
stem
cell
transplant
dose
cell
mononuclear
cell
stem
cell
graft
type
intens
pretreat
chemotherapi
less
treatment
associ
increas
risk
use
granulocyt
macrophag
colonystimul
factor
rather
granulocyt
colonystimul
factor
import
risk
factor
confirm
es
gener
occur
set
acut
system
inflamm
patient
report
significantli
elev
level
sever
proinflammatori
cytokin
outcomestreat
prognosi
es
perd
gener
good
especi
autolog
transplant
symptom
recogn
promptli
treatment
initi
earli
cours
howev
allogen
recipi
poorer
outcom
recent
retrospect
singlecent
studi
consecut
firsttim
allogen
recipi
n
develop
es
patient
es
significantli
higher
incid
grade
acut
gvhd
greater
nonrelaps
mortal
vs
well
poorer
overal
surviv
vs
year
posthsct
patient
es
studi
markedli
elev
level
biomark
receptor
famili
interestingli
biomark
strongli
associ
treatmentresist
acut
gvhd
poor
surviv
patient
symptom
sever
day
week
engraft
symptom
often
mild
may
resolv
within
day
onset
without
specif
intervent
persist
sever
symptom
prompt
consider
treatment
corticosteroid
typic
moder
dose
mgkg
per
day
intraven
methylprednisolon
taper
dosag
base
clinic
respons
recommend
patient
demonstr
rapid
clinic
improv
corticosteroid
treatment
delay
recognit
treatment
howev
may
lead
death
sever
case
hsct
recipi
expos
numer
chemotherapeut
agent
associ
lung
injuri
drug
implic
import
risk
factor
mani
acut
lung
injuri
syndrom
discuss
earlier
section
howev
isol
drugspecif
effect
also
consid
differenti
diagnosi
earli
lung
injuri
exampl
delay
pulmonari
toxic
syndrom
dpt
describ
corticosteroidrespons
pulmonari
complic
seen
exclus
highdos
chemotherapi
bischloroethylnitrosurea
cisplatin
cyclophosphamid
follow
rescu
autolog
hsct
treatment
breast
cancer
support
drug
toxic
primari
risk
factor
observ
patient
receiv
convent
dose
rather
high
dose
chemotherapi
regimen
significantli
lower
rate
dpt
vs
symptom
dpt
nonspecif
includ
cough
dyspnea
exert
fever
develop
case
within
first
day
transplant
chest
ct
scan
typic
show
ground
glass
opac
case
surgic
lung
biopsi
perform
patholog
find
alveolar
septal
thicken
interstiti
fibrosi
type
ii
pneumocyt
hyperplasia
endotheli
cell
injuri
seen
find
consist
although
specif
druginduc
lung
injuri
notabl
past
decad
treatment
approach
fallen
favor
sever
studi
fail
demonstr
surviv
benefit
highdos
chemotherapi
regimen
time
period
addit
publish
report
dpt
although
one
specif
type
lung
injuri
syndrom
longer
report
clinician
must
awar
potenti
pulmonari
toxic
relat
drug
exampl
medic
hsct
recipi
may
receiv
transplant
potenti
caus
pulmonari
toxic
includ
bleomycin
busulfan
methotrex
sirolimu
amiodaron
cytarabin
chlorambucil
fludarabin
mitoxantron
rituximab
bortezomib
thalidomid
novel
immunolog
approach
treat
relaps
diseas
checkpoint
inhibitor
eg
nivolumab
pembrolizumab
target
program
cell
ligand
pathway
infus
chimer
antigen
receptor
modifi
cell
also
associ
system
inflamm
acut
lung
injuri
cryptogen
organ
pneumonia
cryptogen
organ
pneumonia
cop
noninfecti
form
lung
injuri
mimic
pneumonia
may
occur
earli
period
hsct
commonli
seen
later
time
point
report
median
time
present
approxim
day
clinic
symptom
present
nonspecif
includ
nonproduct
cough
fever
progress
dyspnea
radiograph
imag
migratori
alveolar
infiltr
bronchovascular
andor
subpleur
distribut
focal
multifoc
ground
glass
opac
linear
band
report
bronchoscopi
help
rule
infecti
etiolog
surgic
lung
biopsi
perform
patholog
find
plug
granul
tissu
alveolar
duct
sac
associ
chronic
interstiti
inflamm
proxim
extens
distal
airway
lumen
diagnost
although
cop
report
autolog
allogen
hsct
case
occur
allogen
hsct
report
mayo
clinic
allogen
transplant
case
cop
identifi
surgic
lung
biopsi
contrast
case
seen
patient
underw
autolog
transplant
contemporari
review
japanes
transplant
registri
allogen
hsct
recipi
case
identifi
studi
grade
acut
gvhd
identifi
import
risk
factor
cop
japanes
registri
studi
also
report
increas
hla
dispar
femaletomal
transplant
peripher
blood
stem
cell
sourc
risk
factor
ric
fludarabinebas
regimen
myeloabl
condit
busulfan
rather
tbi
appear
reduc
cop
risk
cop
gener
steroidrespons
condit
treatment
recommend
cop
similar
recommend
nontranspl
set
involv
administr
corticosteroid
eg
mgkg
prednisolon
slow
taper
month
patient
howev
signific
risk
diseas
recurr
flare
dose
reduct
overal
patient
develop
cop
transplant
inferior
outcom
compar
nontranspl
recipi
past
year
sever
case
acut
fibrin
organ
pneumonia
afop
describ
earli
late
posthsct
period
afop
rare
distinct
type
acut
lung
injuri
requir
patholog
evalu
diagnosi
presenc
diffus
alveolar
damag
organ
pneumonia
extens
diffus
intraalveolar
fibrin
deposit
without
hyalin
membran
characterist
risk
factor
pathogenesi
known
nonhsct
set
afop
associ
autoimmun
disord
malign
infect
drug
toxic
patient
report
present
cough
fever
dyspnea
afop
may
subacut
aggress
cours
rapid
progress
respiratori
failur
thorac
imag
report
find
includ
nodular
infiltr
peripher
multifoc
airspac
opac
progress
symptom
radiograph
abnorm
despit
treatment
broadspectrum
antimicrobi
agent
prompt
consider
surgic
lung
biopsi
resolut
treatment
high
dose
corticosteroid
etanercept
describ
pulmonari
function
test
pft
transplant
may
stratifi
patient
high
risk
posttranspl
respiratori
failur
death
retrospect
studi
almost
patient
undergon
allogen
hsct
fhcrc
period
develop
respiratori
failur
median
day
transplant
mortal
rate
patient
requir
mechan
ventil
exceed
pretranspl
pft
measur
evalu
found
correl
significantli
risk
respiratori
failur
death
investig
found
combin
pft
variabl
forc
expiratori
volum
second
diffus
capac
carbon
monoxid
dlco
superior
discrimin
abil
predict
respiratori
failur
death
compar
singl
measur
dlco
use
establish
patient
lung
function
score
higher
score
greatest
risk
fact
patient
categori
iv
dlco
estim
surviv
less
outcom
especi
poor
patient
categori
ii
iv
receiv
tbi
part
condit
regimen
acut
noninfecti
lung
injuri
syndrom
preengraft
earli
postengraft
period
major
caus
nonrelaps
mortal
hsct
primari
risk
factor
mani
condit
includ
toxic
administ
chemotherapi
radiat
presenc
sever
acut
gvhd
allogen
recipi
initi
enthusiasm
treat
condit
high
dose
immunomodulatori
agent
corticosteroid
etanercept
dampen
result
recent
studi
although
certain
distinct
condit
perd
may
respons
treatment
pretranspl
pft
result
help
risk
stratifi
patient
inform
treatment
approach
futur
novel
tool
proteom
profil
bal
fluid
panel
biomark
may
facilit
earlier
detect
lung
injuri
help
distinguish
infecti
noninfecti
etiolog
perhap
allow
tailor
patientspecif
treatment
approach
